Subjects with genetic mutations in the FMO3 gene exhibit abnormally high TMA levels due to reduced conversion to TMAO, clinically manifesting as trimethylaminuria (fish-odor syndrome) [89]. This evidence concerns the gene FMO3 and trimethylaminuria.